search
Back to results

Cystic Fibrosis Remote Monitoring System

Primary Purpose

Cystic Fibrosis

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
InCourage-Connect
InCourage
Sponsored by
Koronis Biomedical Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cystic Fibrosis

Eligibility Criteria

14 Years - 85 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have a diagnosis of cystic fibrosis
  • Be physically capable of and willing to use the study device
  • Access to an internet connection
  • Access to a mobile device capable of using applications
  • Be familiar with how to utilize a mobile device and/or applications
  • Self-reported CF-related therapy adherence between 25%-75% on a screening questionnaire

Exclusion Criteria:

  • History of solid-organ transplant
  • Inability to speak and read the English language
  • Any contraindication to vest use for airway clearance

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Interactive coaching

    Standard of care coaching

    Arm Description

    Airway clearance therapy using goal setting and interactive feedback.

    Standard of care airway clearance therapy.

    Outcomes

    Primary Outcome Measures

    Airway Clearance Therapy Adherence
    Intervention comparison of adherence measurements: a) to prescribed pressure based upon % of time at prescribed pressure and b) to prescribed duration of treatment based upon % of time using the airway clearance device at prescribed duration (weekly capture).

    Secondary Outcome Measures

    Lung Function
    Intervention comparison of pre and post measures of FEV1 and FVC.
    Quality of Life Measurement
    Intervention comparison based upon pre and post Cystic Fibrosis Questionnaire Revised (CFQ-R). Name of categories/domains CFQ-R: 9 Quality of life domains: Physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions. 3 symptom scales: Weight, respiratory, and digestion. Scaling of items: 5 distinct 4-point Likert scales (e.g., always/often/ sometime/never) Scoring: Scores for each domain; after recording, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.
    CF Respiratory Symptoms
    Intervention comparison based upon pre and post CF Respiratory Symptom Score (CRSS) assessment. The score evaluates four symptoms: cough, sputum, breathlessness and fatigue. Each symptom is scored from one (mild symptoms) to four (severe symptoms). The total symptom score was the summation of all the four symptoms. Scores range from 4 to 16 with 4 being mild to 16 being most severe.

    Full Information

    First Posted
    June 24, 2020
    Last Updated
    June 30, 2020
    Sponsor
    Koronis Biomedical Technologies
    Collaborators
    Johns Hopkins University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04453358
    Brief Title
    Cystic Fibrosis Remote Monitoring System
    Official Title
    Cystic Fibrosis Remote Monitoring System to Support Resource-Limited Communities
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 1, 2020 (Anticipated)
    Primary Completion Date
    July 31, 2021 (Anticipated)
    Study Completion Date
    August 31, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Koronis Biomedical Technologies
    Collaborators
    Johns Hopkins University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The objective of this study is to determine if interactive technology (i.e. virtual coaching) that facilitates vest therapy goal setting and provides positive reinforcement will increase adherence to vest therapy for airway clearance in individuals with CF.
    Detailed Description
    Cystic fibrosis (CF) is a life-limiting multi-system disease primarily characterized by chronic lung infections and pulmonary symptoms such as cough, dyspnea, and chest tightness. Those with CF rely on numerous pharmaceutical and treatment-based therapies as part of their routine care to maintain lung health. Airway clearance, one such treatment-based therapy, uses breathing techniques and various vibrating devices to mobilize lung secretions and is considered a cornerstone of CF care. Vest therapy, a "shaking vest" that applies pressure and high frequency vibrations to the chest wall is the most commonly used technique for airway clearance in the U.S., but adherence to recommended goals for airway clearance is low. Barriers to adherence include the time limitations and unclear goal setting for effective treatment. A previous pilot study by this research team showed that CF patients find the use of airway clearance vests equipped with both pre-set and individually determined programing capabilities as well as electronic monitoring and transmitting capabilities to be acceptable and feasible. Information such as vest-use time, vest pressure measures, programming choices and symptom reporting is captured by these devices and transmitted to health care teams for review as well as provided to patients to provide feedback on treatment goals. This study aims to determine if providing patients with clearly stated treatment goals and the means to monitor and receive positive reinforcing feedback on vest use through interactive technology (i.e. virtual coaching) will improve vest therapy adherence in individuals with CF.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cystic Fibrosis

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    This study is a randomized-comparative study investigating the effectiveness of either low-level virtual coaching vs. high-level virtual coaching in improving airway clearance treatment adherence.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    35 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Interactive coaching
    Arm Type
    Active Comparator
    Arm Description
    Airway clearance therapy using goal setting and interactive feedback.
    Arm Title
    Standard of care coaching
    Arm Type
    Active Comparator
    Arm Description
    Standard of care airway clearance therapy.
    Intervention Type
    Device
    Intervention Name(s)
    InCourage-Connect
    Intervention Description
    This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
    Intervention Type
    Device
    Intervention Name(s)
    InCourage
    Intervention Description
    This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
    Primary Outcome Measure Information:
    Title
    Airway Clearance Therapy Adherence
    Description
    Intervention comparison of adherence measurements: a) to prescribed pressure based upon % of time at prescribed pressure and b) to prescribed duration of treatment based upon % of time using the airway clearance device at prescribed duration (weekly capture).
    Time Frame
    90 days
    Secondary Outcome Measure Information:
    Title
    Lung Function
    Description
    Intervention comparison of pre and post measures of FEV1 and FVC.
    Time Frame
    180 days
    Title
    Quality of Life Measurement
    Description
    Intervention comparison based upon pre and post Cystic Fibrosis Questionnaire Revised (CFQ-R). Name of categories/domains CFQ-R: 9 Quality of life domains: Physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions. 3 symptom scales: Weight, respiratory, and digestion. Scaling of items: 5 distinct 4-point Likert scales (e.g., always/often/ sometime/never) Scoring: Scores for each domain; after recording, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.
    Time Frame
    180 days
    Title
    CF Respiratory Symptoms
    Description
    Intervention comparison based upon pre and post CF Respiratory Symptom Score (CRSS) assessment. The score evaluates four symptoms: cough, sputum, breathlessness and fatigue. Each symptom is scored from one (mild symptoms) to four (severe symptoms). The total symptom score was the summation of all the four symptoms. Scores range from 4 to 16 with 4 being mild to 16 being most severe.
    Time Frame
    180 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    14 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Have a diagnosis of cystic fibrosis Be physically capable of and willing to use the study device Access to an internet connection Access to a mobile device capable of using applications Be familiar with how to utilize a mobile device and/or applications Self-reported CF-related therapy adherence between 25%-75% on a screening questionnaire Exclusion Criteria: History of solid-organ transplant Inability to speak and read the English language Any contraindication to vest use for airway clearance
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Noah Lechtzin, MD
    Phone
    (410) 502-7044
    Email
    nlechtz1@jhmi.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Patrick Lichter
    Phone
    6127301091
    Email
    plichter@koronisbiotech.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Noah Lechtzin, MD
    Organizational Affiliation
    Johns Hopkins University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Cystic Fibrosis Remote Monitoring System

    We'll reach out to this number within 24 hrs